Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-03 03:28:13 - browse：29254

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Canadian Prime Minister Justin Trudeau separating from wife, Sophie

WSS

New safety details link Apellis eye drug to rare cases of blindness

Why some people catch Covid but never get sick

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Amazon expands telehealth clinic nationwide

Mega Millions pot grows to $1.25 billion after no winner

What the airline industry can learn from medicine

focus

Wikipedia

hotspot

The high cost of giving birth even with insurance

Trump got a 'target letter.' What is one and what does it mean?

Peter Hotez and the public health issue of online harassment

Celebrate National Dole Whip Day for 3 days this week at Disney

Virginia high school admissions case could be legal follow

'Reaching a detente': STAT's Helen Branswell on covering Covid

Bright Health sells Medicare Advantage business to Molina

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Psychedelics group wrestles with new pharma identity

Mega Millions pot grows to $1.25 billion after no winner

entertainment

Resistance to cancer drugs: A new genetic explanation

Sage hopes for a blockbuster in antidepressant now before FDA

India sets sights on home

‘Oppenheimer’ and the risks of AI in health care

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Ebola public health emergency is over, WHO declares

focus

hotspot

focus

knowledge